The stem cell factor (SCF)c-kit receptor interaction plays a critical role in the development and survival of mast cells. Several studies have also associated c-kit receptor mutations with the human diseases, mastocytosis and piebaldism. Overexpression of c-kit has been reported to be associated with myeloproliferative disorders and myelodysplastic syndromes. Using peripheral blood mononuclear cells (PBMCs) from 11 patients with indolent mastocytosis (category I), mastocytosis with an associated hematologic disorder (category II), or aggressive mastocytosis (category III); a patient with CMML unassociated with mastocytosis, and PBMCs from 13 normal subjects, we examined the level of expression of c-kit mRNA along with other c-kit isoforms to determine if overexpression of the c-kit receptor was associated with mastocytosis. Using quantitative competitive PCR, c-kit mRNA levels on average were found to be statistically elevated in the five patients with mastocytosis with an associated hematologic disorder and in the patient with aggressive mastocytosis as compared with controls, but not elevated in patients with indolent mastocytosis. The relative mRNA expression for the two c-kit isoforms was not significantly different in the mastocytosis patients compared with controls. This demonstration of the overexpression of c-kit mRNA in mastocytosis, and particularly those patients with clinical evidence of myelodysplastic syndrome, adds evidence to support the conclusion that mastocytosis, at least in some patients, is a feature of myelodysplasia; and suggests that determination of c-kit mRNA expression in PBMCs may provide an additional approach to assessing prognosis.
Introduction
The proto-oncogene c-kit encodes a transmembrane tyrosine kinase receptor for the growth factor, SCF, and belongs to the same family of receptors as those which bind platelet-derived growth factor and colony-stimulating factor-1.
1,2 The common structural feature of this family of receptors is a five immunoglobulin-like loop structure in the extracellular domain and a kinase insert which splits the catalytic domain between the ATP binding site and the phosphotransferase active site. In human c-kit, there are two kinds of isoforms which are generated by alternative splicing. 3 The alternative splice site for the first is located at the 5′ splice junction involving exon 9, thus generating two isoforms of mRNA differing in size by 12 bases; the alternative splice site for the second is located at the 3′ acceptor site involving exon 15 in the kinase insert domain and generates two mRNA isoforms differing in size by three bases. The protein products of the former isoforms differ by four amino acids, Gly-Asn-Asn-Lys (+) or (−), and they are referred to as Kit A and Kit, respectively. Previous murine studies of homologous isoforms have demonstrated that Kit but not Kit A has constitutive weak autophosphorylation activity. 4 Transcripts and protein products of c-kit are expressed on mast cells, 5, 6 hematopoietic stem cells, 6-10 melanocytes [11] [12] [13] Correspondence: DD Metcalfe, NIH/NIAID/LAD, Building 10, Room 11C205, 10 Center Drive, MSC 1881, Bethesda, MD 20892-1881, USA; Fax: 301 480-8384 Received 7 January 1997; accepted 16 October 1997 and germ cell lineages. 12, 14 The c-kit receptor is known to mediate critical signals for the proliferation and maturation of these cells, [15] [16] [17] and recent studies have demonstrated that abnormalities of c-kit are associated with human diseases which are characterized by impaired or enhanced growth of cells expressing this receptor. Mutations of c-kit are involved in the hereditary disease piebaldism, which is characterized by loss of pigmentation, [18] [19] [20] [21] while overexpression of c-kit mRNA is reported to be associated with myeloproliferative disorders and myelodysplastic syndromes (MDS). 22 Mastocytosis is a disease of unknown pathogenesis characterized by mast cell hyperplasia in the bone marrow, liver, spleen, lymph nodes, gastrointestinal tract and skin. 23 It is classified into four categories: (I) indolent mastocytosis, (II) mastocytosis with an associated hematologic disorder, (III) lymphadenopathic mastocytosis with eosinophilia (also known as aggressive mastocytosis), and (IV) mast cell leukemia. Based on the information that the SCF/c-kit receptor system plays a role in the development of mast cells, several studies investigating the role of SCF or the c-kit receptor in the development of mastocytosis have been performed in patients with mastocytosis. Longley et al 24 reported that there is increased soluble SCF in the skin of indolent mastocytosis patients. We recently identified an activating point mutation of c-kit in the peripheral blood mononuclear cells (PBMCs) of patients with mastocytosis with an associated hematologic disorder which was a substitution of Val for Asp-816, the same mutation as one of the two mutations found in the human mast cell leukemia cell line HMC-1. [25] [26] [27] This mutation has now also been reported in the skin of a patient with indolent mastocytosis. 28 Nevertheless, it still remains to be revealed whether there are any abnormalities of c-kit receptor expression in mastocytosis patients. Thus, in the present study, we decided to evaluate the level of expression of c-kit mRNA in patients with mastocytosis to determine whether or not there is overexpression of c-kit. Furthermore, we examined the relative expression of mRNA for Kit and Kit A as well as mRNA for the other isoforms.
Materials and methods

Subjects
All procedures used to obtain human specimens were approved by the National Institute of Allergy and Infectious Diseases (NIAID) Institutional Review Board at the National Institutes of Health and followed informed consent. Blood was obtained from 11 adult patients with mastocytosis, and one adult patient with chronic myelomonocytoic leukemia (CMML) unassociated with mastocytosis. The diagnosis for each patient was based on clinical symptomatology, physical findings, bone marrow biopsy and aspirate, and other appropriate biopsy specimens (Table 1) . Subjects with mastocytosis were divided into those with indolent mastocytosis (five patients total, patients I-1, 2, 3, 4, 5), mastocytosis with an associated hematologic disorder (five patients total, patients II-1, 2, 3, 4, 5), and aggressive mastocytosis (one patient, patient III-1). Eight of these respective mastocytosis patients, (I-1, 2, 3, II-1, 2, 3, 4, III-1), and the patient with CMML (IV-1) are the patients whose PBMCs were screened for c-kit mutations in our previous study, with their clinical features and hematological findings described in that report. 25 Four of these mastocytosis patients (II-1, 2, 3, 4) had the point mutation, Asp816Val, in the catalytic domain of c-kit. An additional fifth patient with mastocytosis with an associated hematologic disorder (II-5) whose PBMCs we recently analyzed for this c-kit mutation was also found to have the same mutation, and her associated hematologic disorder was unclassifiable myelodysplastic syndrome (MDS).
Normal controls consisted of blood obtained from 13 healthy male and female adult volunteers whose ages ranged between 25 and 40 years of age.
RNA extraction and cDNA synthesis
PBMCs were isolated by Ficoll-Hypaque density gradient centrifugation (density 1.077, Sigma Chemical, St Louis, MO, USA). Total RNA was extracted from PBMCs by the acid guanidium phenol-chloroform method, 29 precipitated and kept at −20°C until use. After measurement of the amount of RNA by spectrophotometry, 5 g of each sample was reverse transcribed to cDNA with Moloney murine leukemia virus reverse transcriptase without RNase H activity and oligo dT primer (Life Technologies, Gaithersburg, MD, USA) in 20 l of reaction solution. After reverse transcription, the reaction solution was diluted with deionized water to 100 l, then aliquoted to 10 l, and kept frozen at −80°C until use. To minimize variability of the efficiency of the reverse transcription reaction, all 25 RNA samples from patients and controls were reverse transcribed at the same time. 
Quantitative competitive PCR for c-kit
To determine the level of c-kit mRNA expressed in PBMCs, we performed quantitative competitive PCR (qc-PCR) with reverse transcribed cDNA. The sequence of primers were: primer 1 (sense), 5′GTAAGGCTTACAACGATGTGGGCA 3′(nucleotide 1493-1516 of the published c-kit cDNA sequence 1 ) and primer 2 (anti-sense), 5′ TTGAGCATCTTTACAGCGA-CAGTCA 3′ (1898-1874). To make an internal standard for the qcPCR, PCR products from cDNA were cleaved with the restriction endonuclease Mnl1. Because of the presence of two isoforms, predicted sizes of the PCR products from the two isoforms were 406 and 394 bp, respectively, and the predicted sizes of DNA fragments after Mnl1 cleavage were 202, 132 and 72 bp for Kit A cDNA, and 190, 132 and 72 bp for Kit cDNA ( Figure 1 ). After separation on a 20% polyacrylamide gel, the 190 and 72-bp fragments were excised, purified by the crush and soak method, 30 and ligated to make a 262-bp internal standard. This internal standard, thus, had the same primer sequences as the c-kit cDNA, and competed with the cDNA for primers and other reagents in one tube. The ligated 262-bp DNA fragment was then amplified by PCR with the same primers, separated on a 20% polyacrylamide gel,
Figure 1
Creation of a 262-bp internal competitive standard for qcPCR for c-kit. After PCR of cDNA with primers 1 and 2, PCR products were cleaved with Mnl1 endonuclease. The 190-bp fragments cleaved from isoform 1 and 72-bp fragments from both isoforms were then separated on a polyacrylamide gel, purified, and ligated to make a 262-bp internal standard. Isoform 1 and isoform 2 are the PCR products amplified from mRNA for Kit A and Kit, respectively. EC, extracellular domain; TM, transmembrane; CP, cytoplasmic domain. and purified. The concentration of the purified PCR product was determined by comparison of the intensity of electrophoretic bands on a 1.5% agarose gel against those generated by known quantities of X174/HaeIII digest. The concentration of the PCR product was adjusted to 100 attomole/l (1 attomole = 10 −18 mole) in 50 g/ml glycogen (Boehringer Mannheim Biochemica, Indianapolis, IN, USA) and stored as a stock solution of the internal standard. We performed two sets of qcPCR to quantitate c-kit in each sample as follows: 2 l of cDNA sample, ie cDNA made from 100 ng of total RNA, was amplified for 40 cycles in the presence of 1 l of a 10-fold dilution series of internal standards whose concentrations were 10 −1 to 100 −5 attomole/l (Figure 2a) . After approximating the concentration of standard which would give a 1:1 ratio of the intensity of bands of PCR products amplified from cDNA and standard, cDNA was further analyzed with a two-fold dilution series of standards. After the second PCR, the intensity of bands was assessed with a densitometer (Molecular Dynamics, Sunnyvale, CA, USA), and the concentration of the standard which would give a 1:1 ratio of band intensity was obtained by a statistical analysis with a computer (Figure 2b) . The result was then converted to the amount of the internal standard which would equilibrate with cDNA reverse transcribed from 1 g of total RNA. This value was used to express the amount of c-kit mRNA in 1 g of total RNA.
Studies on isoforms
To visualize the isoforms of c-kit mRNA, radiolabeled PCR products containing the 12 base and three base differing isoforms were separated on a sequencing gel. The primers used for amplification of 12-base differing isoforms were primer 1 and primer 3 (anti-sense), 5′ CCACTGTACTTCATACAT-GGGTTTC 3′ (1692-1668). The predicted sizes of the PCR products were 200 and 188 bp, respectively. The primer sequences for the three base differing isoforms were: primer 4 (sense), 5′ GAATTTTTTGAGAAGAAAACGTGATTC 3′ (2058-2084) and primer 5 (anti-sense), 5′ TTCATGTCCATG-TACTCCATTAGTAC 3′ (2195-2171); hence, the predicted sizes of PCR products were 138 and 135 bp, respectively. One microliter of cDNA was amplified in the presence of 30 nmol/l of ␣-32 P dCTP. The radiolabeled PCR products were then electrophoresed on a 1.5% agarose gel, and a band including both isoforms was cut out and purified through a Suprec-01 column (Takara, Kyoto, Japan). After radioactivity was measured with a liquid scintillation counter, 1000 c.p.m. of each of the purified products were loaded on to a 6% sequencing gel after heat denaturing at 90°C for 3 min. As a size marker for 12 base differing isoforms, a sequencing product was run in parallel. For this purpose, PCR products amplified with primer 6, 5′ GATCCCATCGCAGCTACCGCG 3′ (1-21) and primer 2 were directly sequenced with radiolabeled primer 3 as described. 25 For the three base differing isoforms, PCR products amplified with primer 7, 5′ GTGCTGGAGCTT-TCGGGAAGG 3′ (1808-1828) and primer 5 were directly sequenced with primer 5, and run in parallel with samples. The gel was dried on Whatman 3MM paper, autoradiographed at −70°C, and the density of bands was measured by densitometry.
Figure 2
An example of qcPCR for c-kit. (a) First, cDNA reverse transcribed from 100 ng of total RNA from the PBMCs was amplified with 1 l of a 10-fold dilution series (10 −1 to 10 −5 attomole/l) of competitive standard. Because of the presence of isoforms of c-kit mRNA, PCR products from cDNA containing 406 and 394-bp fragments, which ran in one band, were separated from the 262-bp PCR products derived from competitive standard. Knowing the approximate concentration of standard which would give a 1:1 ratio of the intensity of bands of PCR products from cDNA and standard, cDNA was further analyzed with a two-fold dilution series. (b) The intensity of each band of the second PCR was measured by densitometry. A straight line which represents a relationship of the ratio of the intensity of bands vs the concentration of internal standard was statistically drawn by a computer, and the concentration of the internal standard which would give a 1:1 ratio of bands was obtained. The amount of mRNA in the PBMCs was expressed by the amount of internal standard which would equilibrate with cDNA reverse transcribed from 1 g of total RNA. In this case, the amount of mRNA in 1 g of total RNA was expressed as 1.31 × 10 −3 times 10, ie 1.31 × 10 −2 attomole.
Results
Expression of c-kit mRNA in the PBMCs of patients and controls
We performed qcPCR to determine the level of c-kit mRNA expressed in the PBMCs of patients with mastocytosis and CMML, along with control subjects, and demonstrated that this technique was sensitive enough to be carried out with cDNA synthesized from 100 ng of total RNA. The intensity of bands amplified from c-kit cDNA which contained 406 and 394-bp fragments was stronger when amplified in the presence of a smaller amount of internal standard and weaker when amplified with a larger amount of standard, indicating that the cDNA and internal standard were competitively amplified in the same tube ( Figure 2 ). Two sets of qcPCR were performed for each sample with a 10-fold and a two-fold dilution series of standard, and the results of these two sets of qcPCR did not show any obvious discrepancy ( Figure 2a ). As may be seen in Figure 3 , the level of c-kit mRNA in the PBMCs of 13 controls ranged from 0.21 to 13 × 10 −3 (mean ± s.d. = 3.9 ± 4.3 × 10 −3 ) attomole/g total RNA, and that of five patients with indolent mastocytosis ranged from 1.6 to 23 × 10 −3 (9.0 ± 8.4 × 10 −3 ) attomole/g total RNA. Student's unpaired t-test showed no statistically significant difference between the mean for these two groups. However, the level of c-kit transcripts in the PBMCs of five patients with mastocytosis with an associated hematologic disorder ranged from 7.7 to 34 × 10 −3 (21 ± 9.3 × 10 −3 ) attomole/g total RNA, and the mean level of c-kit transcripts was statistically significant compared to the mean c-kit transcript level in 13 control subjects (P Ͻ 0.01). The levels of c-kit mRNA in the PBMCs of a patient with aggressive mastocytosis and a patient with CMML unassociated with mastocytosis were 21 × 10 −3 and 24 × 10 −3 attomole/g total RNA, respectively.
Expression of mRNA for Kit A and Kit in the PBMCs of patients and controls
To visualize the 12 base differing isoforms of c-kit mRNA, RT-PCR products containing both isoforms (Kit A and Kit) were separated on a 6% sequencing gel. Run with a sequencing reaction product, the PCR products derived from the two isoforms were demonstrated to differ in size by 12 bases (Figure 4 ). After the density of autoradiographic bands as measured by densitometry, the percentage of the 12 base smaller bands was calculated. The ratio of the 12 base smaller bands which was derived from mRNA for Kit was markedly greater than that of the larger ones which were derived from Kit A mRNA in all subjects studied. Furthermore, there was no significant difference in this ratio in the six mastocytosis patients as compared with the five control subjects. The ratio of the density of smaller bands in the five controls ranged from 89.1 ) attomole/g total RNA. Student's unpaired t-test showed no statistically significant difference between controls and the indolent mastocytosis patients. Patients with mastocytosis with an associated hematologic disorder were found to have a statistically significantly greater amount of c-kit mRNA in the PBMCs than controls (P Ͻ 0.01).
to 100% (94.5 ± 4.9%), and was 97.0 and 94.0%, respectively, in two patients with indolent mastocytosis, 88.9 and 91.4% in the two patients with mastocytosis with an associated hematologic disorder, 90.3% in the patient with aggressive mastocytosis, and 88.3% in the patient with CMML unassociated with mastocytosis.
Expression of three base differing isoforms in the PBMCs of patients and controls After RT-PCR using ␣-32 P dCTP with a primer pair flanking the alternative splice site for three base differing isoforms, the radiolabeled PCR products of two isoforms were separated on a 6% sequencing gel ( Figure 5 ). Two bands were observed in each isoform, possibly because Taq DNA polymerase randomly added dATP to the 3′ end of PCR products. 31 The intensity of two bands in each isoform was measured together by densitometry, and the percentage of three base smaller isoforms was calculated. There was no obvious difference in the ratio of three base smaller isoforms between patients and controls; the ratio of the density of three base smaller bands in the five control subjects was 17.1-33% (26.5 ± 6.1%), and 24.5 and 28.3% in the two indolent mastocytosis patients, 25.4 and 25.7% in the two patients with mastocytosis with an associated hematologic disorder, 27.9% in the patient with aggressive mastocytosis, and 28.0% in the patient with CMML unassociated with mastocytosis.
Discussion
In the present study, we demonstrate that the mean level of c-kit mRNA per 1 g of total RNA extracted from PBMCs was statistically significantly elevated in patients with mastocytosis with an associated hematologic disorder compared with controls, but not elevated in patients with indolent mastocytosis. Elevated c-kit mRNA levels are not, however, specific for mastocytosis with an associated hematologic disorder, as the levels of c-kit mRNA in a patient with aggressive mastocytosis and a patient with CMML unassociated with mastocytosis were as high as the mean c-kit mRNA level of the patients with mastocytosis with an associated hematologic disorder (Figure 3) . Moreover, there is a report that the levels of c-kit mRNA in the PBMCs of patients with myeloproliferative disorders and MDS were statistically significantly higher than that of normal controls. 22 Therefore, it appears that such an increase in c-kit mRNA is correlated with the presence of a hematologic disorder and may reflect an expansion of c-kitpositive cells in the peripheral blood. In our experience, the patient with aggressive mastocytosis was also noted to have unique hematologic abnormalities characterized by a dysplastic megakaryocyte lineage, clumped giant hypogranular platelets in the peripheral blood, an increased leukocyte alkaline phosphatase (LAP) score, and diagnosed to have a reactive marrow. 25 In the human hematopoietic system, a population of CD34 + stem cells expresses c-kit receptors. Mast cells, in contrast to neutrophils and other myeloid cells, express c-kit as mature cells. 6, [8] [9] [10] Because there are a small number of CD34 + cells within PBMCs, and there are no circulating mast cells in normal circumstances, CD34
+ cells are considered to represent the majority of c-kit expressing cells in the PBMCs in normal subjects. [32] [33] [34] [35] [36] As mastocytosis progresses, however, this situation changes as immature mast cells are identified in periph-
Figure 4
Expression of the 12 base differing isoforms of c-kit in patients and controls. PCR products amplified with primers 1 and 3, which are flanking the alternative splice site for the 12 base differing isoforms, were labeled with ␣-32 P dCTP by direct incorporation. PCR products derived from the two isoforms were then separated on a 6% sequencing gel. A sequence on the right side is of a PCR product sequenced with primer 3. Because smaller isoforms comprise the consensus sequence, the sequence of primer 1 appears at the level of 12 base smaller isoforms. 
Figure 5
Expression of three base differing isoforms of c-kit in patients and controls. PCR products amplified with primers 4 and 5, which are flanking the alternative splice site for the three base differing isoform, were labeled with ␣-32 P dCTP and separated on a 6% sequencing gel. A sequence on the right side is of a PCR product sequenced with primer 5. Because both isoforms comprise templates for sequencing, the same sequence repeatedly appears three bases apart. Two bands are seen in each isoform, possibly because Taq DNA polymerase randomly added dATP to the 3′ end of PCR strands. 28 The eral blood, and because mast cells as they differentiate rapidly become CD34 − . 22, 35 Hence, overexpression of c-kit in mastocytosis may be due to both an increase in the number of CD34 + cells and an increase in mast cells and mast cell precursors as detected on bone marrow aspirates and evaluation of peripheral blood smears. 25, 28, 32 We asked the additional question of whether or not there is altered expression of isoforms of c-kit mRNA, as isoforms of c-kit receptors are known to have different baseline activities. Kit but not Kit A is known to have weak constitutive autophosphorylation activity and is known to associate with PI-3′ kinase and PLC␥1 4 -important intermediaries in the signal transduction pathway of the mast cell. In this study, the relative expression level of mRNA for these two isoforms was not obviously different in patients as compared with controls. Likewise, there was no change in the relative level of mRNA for three base differing isoforms among patients and controls. These data suggest that the relative levels of Kit and Kit A are unlikely to contribute to an increase in mast cell number in mastocytosis patients. There are two previous reports which discuss the relative expression of isoforms of c-kit mRNA. Crosier et al 3 studied the relative levels of both 12 base and three base differing isoforms in normal tissue, transformed cell lines and acute myelogenous leukemia (AML) blasts, and reported that 12 base larger transcripts were 10-to 15-fold more abundant than 12 base smaller ones and three base differing transcripts were coexpressed with dominance of three base larger transcripts in all subjects studied; these data are consistent with our results. Another study showed that the relative levels of 12 base smaller transcripts compared to larger isoforms in AML blasts are variable with values ranging from as low as 1.3 to as high as 11.8, while the ratio of these isoforms in normal bone marrow was tightly clustered between 4.4 and 5.5. 37 Both studies concluded that the 12 base and/or three base differing isoforms have no significance in AML blasts and transformed cell lines. Thus, the production of these isoforms may occur along with physiological processes in bone marrow development.
In summary, patients with mastocytosis showed no clear abnormalities in the relative expression level of isoforms of ckit in the PBMCs. On average, however, patients with mastocytosis with an associated hematologic disorder and aggressive mastocytosis had elevated levels of c-kit mRNA. Furthermore, clinical features of indolent mastocytosis and other categories of mastocytosis are known to be distinct, although patients with indolent disease are sometimes reclassified. 23 Mastocytosis with an associated hematologic disorder and aggressive mastocytosis have a more rapid course of disease, poorer prognosis and are not always associated with skin involvement. Conversely, most patients with indolent mastocytosis have a more optimistic prognosis and show urticaria pigmentosa, telangiectasia macularis eruptiva perstans (TMEP) or diffuse cutaneous mastocytosis at some time in their clinical course. These findings suggest that varied pathological processes may underlie the different categories of mastocytosis, but that in some patients, mastocytosis is a concomitant of a dysplastic process, one manifestation of which is the overexpression of c-kit.
